Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV study of Raptiva (efalizumab) in moderate to severe plaque psoriasis
2006-004547-35Phase 4Completed
- Sponsor
- Serono
- Start
- Nov 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, single-arm trial of efalizumab in plaque psoriasis, sponsored by Serono. Primary endpoint: PASI 75 response at week 12. Started Nov 2006; status: completed.
02
Drugs
efalizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2006-004547-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004547-35.